Shree Ganesh Rem

Shree Ganesh Remedies reported robust sequential growth in Q4 FY26, with revenue from operations increasing 57% QoQ to INR 33.20 crore, compared to INR 21.11 crore in Q3 FY26. EBITDA also saw a significant QoQ jump of 69% to INR 11.37 crore, and PAT more than doubled, growing 103% QoQ to INR 6.27 crore. Despite this strong quarterly performance, management noted that FY26 was a year of consolidation, without material top-line expansion on a full-year basis, reflecting deliberate groundwork rather than aggressive growth.

The company achieved a significant milestone in its CRAMS business by successfully completing pilot trials for projects in Europe and Japan. These projects are now transitioning to commercial trial stages, subject to necessary customer and regulatory approvals. Management emphasized that CRAMS remains a central pillar of their long-term strategy, with expectations for this segment to contribute more visibly in the coming years. They highlighted their multi-chemistry expertise, particularly in halogenation and reduction, as a key differentiator for CRAMS engagements.

The Block-7 expansion program is on track, with commercial production anticipated to commence in Q2 FY27. This new facility is designed to support niche and CRAMS molecules. Additionally, the pilot facility commissioned earlier in the year is now fully operational, aiding new product development. Current overall consolidated capacity utilization stands at 60-70%, with Block-8 operating at roughly 50% and expected to reach full capacity by the end of FY27. The next major expansion, the Dahej plant, is in its construction phase and is expected to start after the Ankleshwar unit (Block-7) is fully utilized, with commissioning projected in 16-20 months.

The company continues to face challenging market conditions, including a slowdown in Europe, persistent geopolitical volatility^🌐, and volatile raw material prices, particularly crude oil impacting solvent costs. These factors have led to customers deferring purchases and prolonged regulatory approval timelines, especially for European and pharma products. While Q4 FY26 EBITDA margins were 34.3%, management guided for sustainable normal margins in the range of 26-28% for the longer term, attributing current higher margins to initial product approvals in CRAMS.

Shree Ganesh Remedies positions itself as a chemistry-driven manufacturing partner, focusing on Spec-Chem and Agrochemicals. They aim to cater to high-end customers and innovators, particularly in Europe, Japan, and the USA, where their multi-step chemistry capabilities provide an edge. The company avoids direct competition in finished pharmaceutical products or small molecules, instead concentrating on niche intermediates where competition is limited, especially from Indian players.